Henzen-Logmans, S.C.

cancer patient breast breast cancer mutation tumor women response prophylactic mastectomy group level brca 1 protein brca 2 mutation mastectomy status analysis pai -2 study prognostic tamoxifen prophylactic therapy tp 53 mutation chemotherapy adjuvant surveillance model table value treatment factor plasminogen adjuvant therapy 0.0001 multivariate menopausal status system receptor urokinase result percent node-positive patients disease tp 53 breast cancer patients upa system prognosis activator follow-up number surveillance group tp 53 mutations month analyses survival tp 53 gene prognostic value interval tamoxifen treatment urokinase system tissue urokinase-type plasminogen activator incidence nodal status menopausal multivariate analysis tamoxifen therapy prognostic factors tumor size 1995. node-negative inhibitor relationship component copyright 2001 massachusetts variable relapse prognostic score pai -2 levels